Extremely expensive Biogen rare disease drug could invite tweet by President-elect Trump, analyst says

At up to $750,000 in the first year, Spinraza could be ‘straw that breaks the camel’s back,’ one Wall Street analyst suggested.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.